Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer
Norihiro Yamaguchi(Rockefeller University), Daniel B. Costa(Beth Israel Deaconess Medical Center)
Cited by 93
Related Papers
Assessment of Resistance Mechanisms and Clinical Implications in Patients With<i>EGFR</i>T790M–Positive Lung Cancer and Acquired Resistance to Osimertinib
|JAMA Oncology|2018|689
CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib
|Journal of Clinical Oncology|2011|590
Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer
|Science Translational Medicine|2013|565
BIM Mediates EGFR Tyrosine Kinase Inhibitor-Induced Apoptosis in Lung Cancers with Oncogenic EGFR Mutations
|PLoS Medicine|2007|490
Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2011|379